跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2016-001499-31-BE
EUCTR2016-001499-31-BE进行中（未招募）1 期

A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP

YSARC0 个研究点目标入组 201 人开始时间: 2020年4月15日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
201
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •___Cohort DLBCL : 1. Patients with an untreated DLBCL de novo or transformed from indolent lymphoma (CD 20 positive) Or CD20+ Follicular lymphoma grade 3B with
  • •- Phase Ib aaIPI = 2
  • •- Phase II: aaIPI = 1
  • •2. Age between 60 and 80 years included
  • •____Cohort FOLLICULAR :
  • •1. High Tumor Burden (at least one GELF criteria except isolated elevated LDH at baseline) frontline follicular lymphoma (FL) with high risk FLIPI 3-5
  • •2.Aged between 18 years and 80 years included
  • •11 bis. Females of childbearing potential (FCBP) must agree to use one reliable form of contraception or to practice complete abstinence from heterosexual contact during the following time periods related to this study: 1) for at least 28 days before starting study drug; 2) while participating in the study; 3) dose interruptions; and 4) for at least 12 months after discontinuation of any study treatment (R-CHOP, tazemetostat, Rituximab)
  • •____Both cohorts DLBCL and Follicular :
  • •1bis. For phase II patients: Bi-dimensionally measurable disease defined by at least one single node or tumor lesion > 1.5 cm assessed by CT scan and/or clinical examination AND a FDG avid disease by PETscan
  • •3. ECOG performance status of 0, 1 or 2 (0 or 1 only for phase Ib)
  • •4. Signed informed consent
  • •5. Life expectancy of = 90 days (3 months) before starting tazemetostat
  • •6. Adequate renal function as calculated by a creatinine clearance > 40 mL/min by local institutional formula
  • •7. Adequate bone marrow function as defined as:
  • •- ANC = 1500/mm3 (= 1.5 X 109/L)
  • •- Platelets = 75,000/mm3 (= 75 X 109/L) without platelet transfusion dependency during the last 7 days
  • •-Hemoglobin = 9 g/dL (may receive transfusion)
  • •8. Adequate liver function as defined as:
  • •- Total bilirubin = 1.5 × the upper limit of normal (ULN) except for unconjugated hyperbilirubinemia of Gilbert’s syndrome
  • •- Alkaline phosphatase (in absence of bone disease), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 3 X ULN (or = 5 X ULN if related to lymphoma involvement)
  • •-Patients with prior Hepatitis B and C are eligible if, for Hepatitis B detection, surface antigen is negative and/or HBV DNA is undetectable, and for Hepatitis C detection, if HCV RNA is undetectable.
  • •- 9. Left ventricular ejection fraction (LVEF) > 50% of echocardiography or multiple gated acquisition (MUGA) scan
  • •- 10. Adequate tissue (surgical excision is recommended) for central pathology review and biological caracterisation
  • •11. Males with partners of childbearing potential must agree to use
  • •reliable forms of contraception during 12 months after last treatment
  • •administration
  • •12. Patient covered by any social security system (for France only)
  • •13. Patient who understands and speaks one of the country official languages
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 33
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 100

排除标准

  • •___Both cohorts:
  • •1. Central nervous system or meningeal involvement
  • •2. Contraindication to any drug contained in the chemotherapy regimen
  • •3. Prior treatment with tazemetostat or other inhibitor of EZH2
  • •4. Patients who are undergoing active treatment for another malignancy, exceptions include: A patient who has been disease free for 2 years, or a patient with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible
  • •Patients with prior history of myeloid malignancies, including myelodysplastic syndrome (MDS) or Acute Myeloid Leukemia(AML)or prior history of T-LBL/T-ALL are excluded whatever receiving treatment or not and whatever date of diagnosis of these pathologies
  • •5. Patients taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John’s wort)
  • •6. Patients unwilling to exclude St. John’s wort, Seville oranges, grapefruit juice and/or grapefruit from diet
  • •7. Major surgery within 4 weeks before first dose of study drug (minor procedures including transcutaneous biopsy, central line placement are permitted within 2 weeks of enrollment)
  • •8. Inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would impare ability to take tazemetostat
  • •9. Significant cardiovascular impairment: congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or stroke within 6 months of first dose of tazemetostat or ventricular arrhythmia
  • •10. NOt applicable
  • •11. Active uncontrolled infection requiring systemic therapy
  • •12. Congenital immunodeficiency or known HIV (human immunodeficiency virus infection)
  • •13. Any other major illness, that in the investigator’s judgement, will substantially increase the risk associated with the patient’s participation in the study
  • •14. Patients who have undergone a solid organ transplant
  • •16. Treatment with any investigational drug or device within 30 days before planned first cycle of chemotherapy
  • •18. Person deprived of his/her liberty by a judicial or administrative decision
  • •19. Adult person under legal protection
  • •20. Person hospitalized without consent
  • •21. Adult person unabled to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
  • •___DLBCL cohort
  • •15. Previous treatment for B cell lymphoma, except glucocorticoids (no more than 7 days before inclusion, 1 mg/kg/day max)
  • •___ Follicular cohort
  • •15. Prior therapy for lymphoma including radiotherapy except glucocorticoids (no more than 7 days before inclusion, 1mg/kg/day max)
  • •17. Pregnant or lactating females

研究者

发起方
YSARC

相似试验

进行中（未招募）
1 期
Study of tazemetostat in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients treated by R-CHOP
EUCTR2016-001499-31-FRYSARC133
进行中（未招募）
1 期
A Study on the Effect of Tazemetostat (study drug) in Pediatric Subjects withwith relapsed or refractory Tumors or Synovial SarcomaAtypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK), selected tumors with rhabdoid features.Epithelioid sarcoma, Epithelioid malignant peripheral nerve sheath tumor, Extraskeletal myxoid chondrosarcoma, Myoepithelial carcinoma, Renal medullary carcinoma, Other INI1-negative malignant tumors (e.g., dedifferentiated chordoma) with Sponsor approval, Synovial Sarcoma with a SS18-SSX rearrangementMedDRA version: 21.1Level: LLTClassification code 10064886Term: Renal medullary carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10065870Term: Atypical teratoid/rhabdoid tumor of CNSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10073134Term: Extraskeletal myxoid chondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074121Term: Rhabdoid tumor of the kidneySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10015100Term: Epithelioid sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-002468-18-GBEpizyme, Inc.120
进行中（未招募）
1 期
A Study on the Effect of Tazemetostat (study drug) in Pediatric Subjects with relapsed or refractory Tumors or Synovial Sarcoma
EUCTR2015-002468-18-DKEpizyme, Inc.120
进行中（未招募）
1 期
A Study on the Effect of Tazemetostat (study drug) in Pediatric Subjects withwith relapsed or refractory Tumors or Synovial Sarcoma
EUCTR2015-002468-18-NLEpizyme, Inc.120
进行中（未招募）
1 期
A Study on the Effect of Tazemetostat (study drug) in Pediatric Subjects with relapsed or refractory Tumors or Synovial SarcomaAtypical teratoid rhabdoid tumor (ATRT), Malignant rhabdoid tumor (MRT), Rhabdoid tumor of kidney (RTK). Outside of Germany : - selected tumors with rhabdoid features- INI-negative tumors or synovial sarcoma: Epithelioid sarcoma, Epithelioid malignant peripheral nerve sheath tumor, Extraskeletal myxoid chondrosarcoma, Myoepithelial carcinoma, Renal medullary carcinoma, other INI1-negative malignant tumors (like dedifferentiated chordoma), Synovial Sarcoma with a SS18-SSX rearrangement.MedDRA version: 21.1Level: LLTClassification code 10064886Term: Renal medullary carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10065870Term: Atypical teratoid/rhabdoid tumor of CNSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10073134Term: Extraskeletal myxoid chondrosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10073335Term: Rhabdoid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10074121Term: Rhabdoid tumor of the kidneySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10015100Term: Epithelioid sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-002468-18-DEEpizyme, Inc.120